Executive Summary The use of Precision Medicine (PM) is increasing across Asia at a pace that outstrips the capacity of existing Health Technology Assessment (HTA) and reimbursement systems to respond. The “Workshop on Paying for Precision Medicine Sustainably in Asia: Reimbursement Barriers, Ena

The Standard Cost List for Health Technology Assessment in Thailand provides the foundational cost data for Health Technology Assessment (HTA) and economic evaluation studies. It supplies robust, context-specific cost data to inform evidence-based policy, specifically for developing and revising benefit packages under Thailand’s Universal Coverag

EXECUTIVE SUMMARY  The Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand, undertook a mission to Colombo, Sri Lanka, supported by the World Bank Group. The mission aimed to support national efforts to strengthen capacity on health priority setting and institutiona

Abstract Understanding the financial and health consequences if economic evaluation assumptions prove incorrect is essential for managing the risk associated with benefit package decisions, particularly in resource-constrained and overburdened healthcare systems. Yet these are also the settings t

Abstract Health technology faces rising costs, system complexities, and gaps between development and coverage policies, limiting translation into practice. Traditional health technology assessment (HTA) evaluates technologies at late stages, providing little support if a technology fails to secur

The research and development of new medicines is a lengthy and sequential process that spans more than a decade, culminating in regulatory approval based on evidence of quality, safety, and efficacy from clinical trial data. In Thailand, it takes nearly an additional decade for new medicines to be included in the Thailand National List of Essential

Antimicrobial resistance (AMR) is one of the most pressing public health challenges worldwide. It occurs when antimicrobials—such as antibiotics, antifungals, antivirals, and antiparasitics—become ineffective against microorganisms like bacteria, fungi, viruses, and parasites. This resistance can le

Tuberculosis is caused by bacterium called Mycobacterium tuberculosis. It is a significant problem in Thailand as seen that in 2021 Thailand is in the World Health Organization’s list of 30 high-burden countries for tuberculosis. One of the problems about tuberculosis is inaccurate diagnosis due to insufficient sensitivity and specificity of prim

The development of medical innovation is one of Thailand’s key strategic priorities, as outlined in the 13th National Economic and Social Development Plan (2023–2027), with Milestone 4 positioning Thailand as a hub for high-value medical and healthcare services. However, Thailand’s research and development in medical technologies and health i

The project aims to evaluate the cost-effectiveness, economic impact, and feasibility of integrating this herbal innovation into Thailand’s healthcare system. By applying Early HTA techniques, this study will provide insights for decision-makers, improve resource allocation, and support future investments in innovative medical solutions.67301075M